NewLink to get $20 million in Ebola vaccine research milestone

NewLink Genetics will receive $20 million for a research milestone in its work with Merck to develop an Ebola vaccine. | NewLink Genetics

NewLink Genetics said on Thursday that it had reached a milestone in its development of an Ebola vaccine, and will receive a $20 million payment as a result.

The milestone, listed in a license and collaboration agreement with Merck, came out of initiating a clinical trial for the rVSV-EBOV vaccine that the two companies are developing.

“We at NewLink very much appreciate the tremendous support for these studies that we have received from our collaboration partners, including Merck, the government of Canada and the U.S. Department of Health and Human Services (Centers for Disease Control, the National Institutes of Health and the Biomedical Advanced Research and Development Authority), the U.S. Department of Defense and the World Health Organization, each of which has made critical contributions along the way,” Dr. Charles Link, NewLink Genetics' chairman, CEO and chief scientific officer, said. “We hope that the initiation of large-scale clinical trials in Africa represents another step forward toward finding a solution for this difficult, global problem. This milestone payment will help us continue our significant investment into vaccines for infectious diseases, including Ebola, in collaboration with Merck.”

The Public Health Agency of Canada originally developed the vaccine, which was licensed to BioProtections Systems, a wholly owned subsidiary of NewLink Genetics.

Organizations in this story

Merck 2000 Galloping Hill Rd Kenilworth, NJ 07033

U.S. Department of Defense 2 N Rotary Rd Arlington, VA 22202

National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892

Get notified the next time we write about any of these organizations!